RedDress was selected among 20 Israeli startup companies as one of the Top Promising Israeli Startups of 2020 – a humbling honor for the RedDress team and its founders, Dr. Igal Kushnir and his son, Alon Kushnir.
For its list, The Marker selects 20 Israeli startups that confront the greatest challenges facing humanity. For RedDress, the challenge is chronic, non-healing wounds.
Chronic, non-healing wounds are wounds that refuse to respond to medical treatment – they don’t heal, or heal slowly, because an underlying defect impedes local blood flow to the wound site and hinders the body’s natural wound healing process.
Dr. Igal Kushnir, 74, a pediatrician and veteran in the startup world, conceived the idea that acute wounds heal quickly due to the body’s natural healing process, whereas chronic wounds are simply forgotten by the body at some point in the healing process.
With his son Alon – who is highly experienced in the management of medical startups – he developed a unique process for delivering a point of care, biologic wound care solution – ActiGraft® – that transforms a patient’s blood into an autologous clot tissue that supports the body’s natural wound healing processes.
ActiGraft is an FDA and CE-cleared, wound solution that enables health care providers to produce – in real time – in vitro blood clot tissue from a patient’s whole blood. Once applied, the blood clot tissue serves as a protective covering and supports wound healing processes which naturally occur in the patient's body.
With the clinical study submitted to FDA showing a 72% healing rate, RedDress is committed to improving the health and lives of patients around the world by revolutionizing the way chronic wounds are treated.
To learn more about The Marker’s nomination and RedDress’ revolutionary wound solution, click here.